The effect of Theiler's murine encephalomyelitis virus (TMEV) VP1 carboxyl region on the virus-induced central nervous system disease

1995 ◽  
Vol 1 (5-6) ◽  
pp. 411-411
Author(s):  
Andrea Serkowski ◽  
Benjamin Shim ◽  
Raymond P Ross
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Central Nervous System Disease ◽  
Nervous System Disease ◽  
Theiler's Murine Encephalomyelitis Virus ◽  
Theiler’S Murine Encephalomyelitis Virus ◽  
System Disease ◽  
Encephalomyelitis Virus

Raccoon Roundworm Infection Associated with Central Nervous System Disease and Ocular Disease — Six States, 2013–2015

2016 ◽  
Vol 65 (35) ◽  
pp. 930-933 ◽  
Author(s):  
Anita D. Sircar ◽  
Francisca Abanyie ◽  
Dean Blumberg ◽  
Peter Chin-Hong ◽  
Katrina S. Coulter ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Central Nervous System Disease ◽  
Ocular Disease ◽  
Nervous System Disease ◽  
System Disease

scholarly journals Emerging Pharmacological Treatments for Cerebral Edema: Evidence from Clinical Studies

2020 ◽  
Vol 60 (1) ◽  
pp. 291-309 ◽  
Author(s):  
Jesse A. Stokum ◽  
Volodymyr Gerzanich ◽  
Kevin N. Sheth ◽  
W. Taylor Kimberly ◽  
J. Marc Simard
Keyword(s):  
Central Nervous System ◽  
Clinical Trials ◽  
Nervous System ◽  
Cerebral Edema ◽  
Clinical Studies ◽  
Central Nervous System Disease ◽  
Ancient Egypt ◽  
Nervous System Disease ◽  
Pharmacological Treatments ◽  
System Disease

Cerebral edema, a common and often fatal companion to most forms of acute central nervous system disease, has been recognized since the time of ancient Egypt. Unfortunately, our therapeutic armamentarium remains limited, in part due to historic limitations in our understanding of cerebral edema pathophysiology. Recent advancements have led to a number of clinical trials for novel therapeutics that could fundamentally alter the treatment of cerebral edema. In this review, we discuss these agents, their targets, and the data supporting their use, with a focus on agents that have progressed to clinical trials.

Catalytic nanozymes for central nervous system disease

2021 ◽  
Vol 432 ◽  
pp. 213751
Author(s):  
Ke Chen ◽  
Si Sun ◽  
Junying Wang ◽  
Xiao-Dong Zhang
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Central Nervous System Disease ◽  
Nervous System Disease ◽  
System Disease
Sign in / Sign up

Export Citation Format

Share Document